YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
ProKidney Seven abstracts spanning CKD translational model studies and drug product characterization provide converging evidence supporting a multifactorial mechanism of action for rilparencel One clinical abstract presents a new pooled Ph…
On August 10, ProKidney Corp. (NASDAQ:PROK) reported second-quarter financial results that doubled as a status update on the biggest bet in its history: a cell therapy for chronic kidney disease that is now one step closer to a verdict. Th…
A study suggests high borrow costs are a good indicator that a stock will lag the broader market. - Getty Images/iStock Certain stocks are such poor bets that they are likely to lose ground even in bull markets. These "loser" stocks are on…
ProKidney Corp. (PROK) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.13 per share a year ago. These figures are adjusted for non-recurring items. Thi…
ProKidney Completed enrollment of patients contributing to the Phase 3 PROACT 1 accelerated approval efficacy analysis, positioning the Company for anticipated pivotal eGFR slope topline results in Q2 2027 On track for completion of full e…
ProKidney Corp. (NASDAQ:PROK) is one of the small-cap stocks with potential to rise 1000 percent. The company's main story centers on rilparencel, its experimental cell therapy for patients with advanced chronic kidney disease and type 2 d…
The market remained flat over the last week, but it is up 26% over the past year, with earnings forecast to grow by 16% annually. For investors willing to look beyond the big names, penny stocks can present intriguing opportunities for gro…
ProKidney Kenneth Locke joins as Chief Technical Officer, bringing more than 25 years of experience across Chemistry, Manufacturing and Controls (CMC) and Supply Chain as ProKidney progresses toward the potential commercialization of rilpa…
* ProKidney press release [https://seekingalpha.com/pr/20517549-prokidney-reports-first-quarter-2026-financial-results-and-business-highlights] (PROK [https://seekingalpha.com/symbol/PROK]): Q1 GAAP EPS of -$0.14 beats by $0.01. * Revenue…
ProKidney Corp. (PROK) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.13 per share a year ago. These figures are adjusted for non-recurring items. Thi…
ProKidney On track to complete enrollment for the Phase 3 PROACT 1 accelerated approval analysis of rilparencel in mid-2026; anticipate pivotal topline results in Q2 2027 Peer-reviewed results from the Phase 2 REGEN-007 study were publishe…
ARS Pharmaceuticals, Inc. (SPRY) came out with a quarterly loss of $0.61 per share versus the Zacks Consensus Estimate of a loss of $0.53. This compares to a loss of $0.35 per share a year ago. These figures are adjusted for non-recurring…
Karyopharm Therapeutics (KPTI) came out with a quarterly loss of $1.24 per share versus the Zacks Consensus Estimate of a loss of $1.45. This compares to a loss of $2.77 per share a year ago. These figures are adjusted for non-recurring it…
June S&P 500 E-Mini futures (ESM26) are trending up +0.46% this morning as investors shrugged off an exchange of fire between the U.S. and Iran and awaited the release of the key U.S. jobs report. The U.S. military said on Thursday that Ir…
The market has climbed 1.8% in the last 7 days and is up 30% over the past year, with earnings projected to grow by 16% annually. Penny stocks, while a somewhat outdated term, continue to represent intriguing investment opportunities for t…
ProKidney Corp. (NASDAQ:PROK) is one of the best biotech penny stocks to buy in 2026. On March 25, ProKidney appointed Greg Madison as Chief Commercial Officer, a move aimed at preparing the company for the potential launch of its lead cel…
Over the last 7 days, the U.S. market has risen by 1.9%, contributing to a 24% increase over the past year, with earnings projected to grow by 15% annually in the coming years. In such a thriving market, identifying stocks with solid finan…
ProKidney Corp. (NASDAQ:PROK) is one of the 10 best penny stocks that could triple your money. On March 19, ProKidney Corp. (NASDAQ:PROK) announced fourth-quarter revenue of $893,000 against consensus estimates of $600,000. The company pro…
ProKidney Veteran commercial executive brings deep nephrology and specialty biopharma leadership experience as ProKidney advances rilparencel toward potential commercialization WINSTON-SALEM, N.C., March 25, 2026 (GLOBE NEWSWIRE) -- ProKid…
(RTTNews) - ProKidney Corp. (PROK), a clinical-stage cell therapy company focused on chronic kidney disease or CKD, reported financial results for the full year 2025 and provided business highlights about its lead investigational candidate…
ProKidney On track to complete enrollment for the Phase 3 PROACT 1 accelerated approval analysis of rilparencel in mid-2026; anticipate pivotal topline results in Q2 2027 In a July 2025 Type B meeting, aligned with FDA on the accelerated a…
Korro Bio, Inc. (KRRO) came out with a quarterly loss of $5.32 per share versus the Zacks Consensus Estimate of a loss of $1.93. This compares to a loss of $2.26 per share a year ago. These figures are adjusted for non-recurring items. Thi…
Aquestive Therapeutics (AQST) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.19 per share a year ago. These figures are adjusted for non-recurring ite…
The chronic kidney disease market growth is being driven by the rising global prevalence of diabetes, hypertension, and aging populations. Increasing awareness and earlier diagnosis are expanding the pool of patients eligible for treatment…
As U.S. stock indexes have started February on a high note, with the Dow Jones Industrial Average and S&P 500 showing impressive gains, investors are closely watching for opportunities in various market segments. Penny stocks, while often…
Major U.S. stock indexes have recently pulled back after setting fresh all-time highs, reflecting a complex economic landscape influenced by geopolitical events and fluctuating oil prices. In this climate, investors often seek opportunitie…
ProKidney WINSTON-SALEM, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD), today announced tha…
ProKidney Corp. (NASDAQ:PROK) is among the Best Get Rich Fast Stocks to Buy Right Now. As of December 24, ProKidney Corp. (NASDAQ:PROK) has a “buy” rating from slightly more than half of the analysts covering the stock. While the price tar…
As the U.S. stock market experiences a slight uptick following a break in its recent winning streak, investors are closely monitoring the tech and crypto sectors for signs of rebound. Penny stocks, though often seen as remnants of past mar…
Key Insights ProKidney's significant retail investors ownership suggests that the key decisions are influenced by shareholders from the larger public A total of 25 investors have a majority stake in the company with 49% ownership Insiders…
ProKidney Full results from the Phase 2 REGEN-007 study of rilparencel were recently presented as a late-breaking clinical trial at the American Society of Nephrology (ASN) Kidney Week 2025 More than half of the patients required for the P…
Full results from the Phase 2 REGEN-007 study of rilparencel were recently presented as a late-breaking clinical trial at the American Society of Nephrology (ASN) Kidney Week 2025More than half of the patients required for the Phase 3 REGE…
ProKidney In patients with advanced chronic kidney disease (CKD) and diabetes, treatment with rilparencel resulted in statistically significant and clinically meaningful slowing of CKD progression Bilateral kidney injection with rilparence…
In patients with advanced chronic kidney disease (CKD) and diabetes, treatment with rilparencel resulted in statistically significant and clinically meaningful slowing of CKD progressionBilateral kidney injection with rilparencel resulted…
WINSTON-SALEM, N.C., Oct. 29, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that…
ProKidney WINSTON-SALEM, N.C., Oct. 29, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today anno…